Loading...
TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
Interaction of myeloma cells with the bone marrow microenvironment is mediated in large part through different cytokines, especially VEGF and IL6. These cytokines, especially IL6, leads to up-regulation of the JAK/STAT pathway in myeloma cell, contributing to increased proliferation, decreased apopt...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2940994/ https://ncbi.nlm.nih.gov/pubmed/20652971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21785 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|